A national survey of the molecular epidemiology of Clostridium difficile in Israel: The dissemination of the ribotype 027 strain with reduced susceptibility to vancomycin and metronidazole

Diagnostic Microbiology and Infectious Disease

Volumn 83, Issue 1, 2015, Pages 21-24

  Adler, Amos ^a   Miller Roll, Tamar ^a   Bradenstein, Rita ^b   Block, Colin ^c   Mendelson, Bracha ^d   Parizade, Miriam ^e   Paitan, Yossi ^f   Schwartz, David ^g   Peled, Nehama ^h   Carmeli, Yehuda ^a   Schwaber, Mitchell J ^a  

^a MINISTRY OF HEALTH   (Israel)

^b KAPLAN MEDICAL CENTER   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d BNAI ZION MEDICAL CENTER   (Israel)

^e MACCABI HEALTHCARE SERVICES   (Israel)

^f MEIR MEDICAL CENTER   (Israel)

^g TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^h BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Clostridium difficile; Epidemic clone; Metronidazole; Vancomycin

Indexed keywords

METRONIDAZOLE; MOXIFLOXACIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; FECES ANALYSIS; HUMAN; INCIDENCE; ISRAEL; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; ANTIBIOTIC RESISTANCE; CLASSIFICATION; CLINICAL TRIAL; CLOSTRIDIUM INFECTIONS; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTICENTER STUDY; PEPTOCLOSTRIDIUM DIFFICILE; RIBOTYPING;

ANTI-INFECTIVE AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; INCIDENCE; ISRAEL; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MOLECULAR EPIDEMIOLOGY; RIBOTYPING; VANCOMYCIN;

EID: 84938746151     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2015.05.015     Document Type: Article

References (25)

1. Adler A., Schwartzberg Y., Samra Z., Schwartz O., Carmeli Y., Schwaber M.J. Trends and changes in Clostridium difficile diagnostic policies and their impact on the proportion of positive samples: a national survey. Clin Microbiol Infect 2014, 20:O904-O910.
2. Alzahrani N., Johani S.A. Emergence of a highly resistant Clostridium difficile strain (NAP/BI/027) in a tertiary care center in Saudi Arabia. Ann Saudi Med 2013, 33:197-199.
3. Barbut F., Mastrantonio P., Delmée M., Brazier J., Kuijper E., Poxton I. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 2007, 13:1048-1057.
4. Bishara J., Goldberg E., Madar-Shapiro L., Behor J., Samra Z. Molecular epidemiology of clostridium difficile in a tertiary medical center in Israel: emergence of the polymerase chain reaction ribotype 027. Isr Med Assoc J 2011, 13:338-341.
5. Clinical and Laboratory Standards Institute (CLSI) Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard-eighth edition 2012, CLSI, Wayne, PA.
6. Collins D.A., Hawkey P.M., Riley T.V., Asia E. Epidemiology of Clostridium difficile infection in Asia. Antimicrob Resist Infect Control 2013, 2:21.
7. Freeman J., Bauer M.P., Baines S.D., Corver J., Fawley W.N., Goorhuis B., et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010, 23:529-549.
8. Gaynes R., Rimland D., Killum E., Lowery H.K., Ii T.M.J., Killgore G., et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004, 38:640-645.
9. Gerding D.N. Global epidemiology of Clostridium difficile infection in 2010. Infect Control Hosp Epidemiol 2010, 31(Suppl. 1):S32-S34.
10. He M., Miyajima F., Roberts P., Ellison L., Pickard D.J., Martin M.J., et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 2013, 45:109-113.
11. Kato H. Typing by sequencing the slpA gene of Clostridium difficile strains causing multiple outbreaks in Japan. J Med Microbiol 2005, 54:167-171.
12. Kato H., Kato H., Ito Y., Akahane T., Izumida S., Yokoyama T., et al. Typing of Clostridium difficile isolates endemic in Japan by sequencing of slpA and its application to direct typing. J Med Microbiol 2010, 59:556-562.
13. Killgore G., Thompson A., Johnson S., Brazier J., Kuijper E., Pepin J., et al. Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-repeat an. J Clin Microbiol 2008, 46:431-437.
14. Kok J., Wang Q., Thomas L.C., Gilbert G.L. Presumptive identification of Clostridium difficile strain 027/NAP1/BI on Cepheid Xpert: interpret with caution. J Clin Microbiol 2011 Oct, 49(10):3719-3721.
15. Kuijper E.J., Wilcox M.H. Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection?. Clin Infect Dis 2008, 47:63-65.
16. Lemee L., Dhalluin A., Testelin S., Mattrat M., Maillard K., Pons J. Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (toxin A), and tcdB (toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol 2004, 42:5710-5714.
17. McDonald L.C., Killgore G.E., Thompson A., Owens R.C., Kazakova S.V., Sambol S.P., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005, 353:2433-2441.
18. Persson S., Torpdahl M., Olsen K.E.P. New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection. Clin Microbiol Infect 2008, 14:1057-1064.
19. Persson S., Jensen J.N., Olsen K.E.P. Multiplex PCR method for detection of Clostridium difficile tcdA, tcdB, cdtA, and cdtB and internal in-frame deletion of tcdC. J Clin Microbiol 2011, 49:4299-4300.
20. Shah D., Dang M., Hasbun R., Koo H.L., Jiang Z., Dupont H.L., et al. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther 2010, 8:555-564.
21. Simor A.E., Bradley S.F., Strausbaugh L.J., Nicolle L.E., Care T., Simor A.E., et al. Clostridium difficile in long-term care facilities for the elderly. Infect Control Hosp Epidemiol 2002, 11:696-703.
22. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1 2013, [2013pp. http://www.eucast.org].
23. Wiener-well A.Y., Ben-chetrit E., Abed-eldaim M., Marc V., Miller-roll T., Adler A. Clinical and molecular characteristics of an outbreak caused by the pandemic (BI/NAP1/027) Clostridium difficile clone in a single center in Israel. Infect Control Hosp Epidemiol 2014, 35:5-8.
24. Wilcox M.H., Shetty N., Fawley W.N., Shemko M., Coen P., Birtles A., et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin Infect Dis 2012, 55:1056-1063.
25. Xiao M., Kong F., Jin P., Wang Q., Xiao K., Jeoffreys N., et al. Comparison of two capillary gel electrophoresis systems for Clostridium difficile ribotyping, using a panel of ribotype 027 isolates and whole-genome sequences as a reference standard. J Clin Microbiol 2012, 50:2755-2760.